参考文献/References:
1 Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J Nucl Med, 2006, 47(3):451-469.
2 Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol, 2005, 23(21):4652-4661.
3 Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol, 2005, 16(9):1514-1523.
4 Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 2006, 107(1):52-59.
5 Cerfolio R J, Bryant AS, Winokur TS. et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg, 2004, 78(6):1903-1909.
6 Pottgen C, Levegrun S, Theegarten D, et al. Value of 18F-fluoro-2deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res, 2006, 12(1):97-106.
7 Nahmias C, Hanna WT. Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET-CT. J Nucl Med, 2007, 48(5):744-751.
8 Stroobants S, Goeminne J, Seegers M, et al. 18F-DG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinih mesylate (Glivec). Eur J Cancer,2003, 39(14):2012-2020.
9 Goerres GW, Stupp R, Barghouth G. et al. The value of PET, CT and in-line PET-CT in patients with gastrointestinal stromal tumours:long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging, 2005, 32(2):153-162.
10 Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dualmodality PET-CT imaging for monitoring of imatinib (ST1571)therapy in patients with gastrointestinal stromal tumors. J Nacl Med, 2004, 45(3):357-365.
11 Buyse M, Thirion P, Carlson RW, et al.Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer:a meta-analysis, Meta-Analysis Group in Cancer. Lancet, 2000, 356(9227):373-378.
12 Goffin J, Baral S, Tu D, et al. Objective responsed in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res, 2005, 11(16):5928-5934.
13 Jerusalem G, Hustinx R, Beguin Y. et al. Evaluation of therapy for lymphoma. Semin Nucl Med, 2005, 35(3):186-196.
14 Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med, 2005, 46(6):983-995.
15 Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer:prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol, 2003, 21(14):2651-2657.
16 Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indictor of therapeutic response in patients in national cancer institute trials. J Nucl Med, 2006, 47(6):1059-1066.
17 Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 2002, 346(4):235-242.
18 Spaepen K, Stroobants S, Dupont P, et al. Early re-staging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol,2002, 13(9):1356-1363.
19 Haioun C,Itti E, Rahmouni A, et al.[18F]fluoro-2-deoxy-D-glucose positron emission tomography(FDG-PET) in aggressive lymphoma:an early prognostic tool for predicting patient outcome. Blood, 2005, 106(4):1376-1381.
20 Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2(stage Ⅲa) non-small cell lung cancer after neoadjuvant chemoradiotherapy:a prospective study. J Thorac Cardiovasc Surg, 2006, 131(6):1229-1235.
21 Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med,2005, 353(2):123-132.
22 Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer:results from a randomized, placebo-controlled, multicentre study(Iressa Survival Evalustion in LungCancer).Lancet, 2005, 366(9496):1527-1537.
23 Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res, 2004, 64(11):3892-3899.
24 Demetri GD, yon Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7):472-480.
25 Weber WA, Figlin R. Monitoring cancer treatment with PET-CT:does it make a difference?. J Nucl Med, 2007, 48(Suppl 1):36S-44S.
26 Young H, Baum R, Cremerius U, et al. Measurement of clinical and sublinical tumour response using[18F]-fluorodeoxyglucose and positron emission tomography:review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer, 1999, 35(13):1773-1782.
27 WeberWA, Ziegler SI, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med, 1999, 40(11):1771-1777.
28 Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging, 2006, 33(Suppl 1):27-37.
相似文献/References:
[1]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[2]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[3]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[6]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[7]张巧娜,刘汉东.上颌窦上皮-肌上皮癌的CT表现一例[J].国际放射医学核医学杂志,2016,40(3):237.[doi:10.3760/cma.j.issn.1673-4114.2016.03.015]
[8]刘淑蓉,孙凯.低辐射剂量冠状动脉成像的研究进展[J].国际放射医学核医学杂志,2016,40(4):293.[doi:10.3760/cma.j.issn.1673-4114.2016.04.011]
Liu Shurong,Sun Kai.The advances of low radiation dose coronary computed tomography angiography imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):293.[doi:10.3760/cma.j.issn.1673-4114.2016.04.011]
[9]郑雪,孙凯.双源双能量CT心肌灌注成像的研究进展[J].国际放射医学核医学杂志,2016,40(4):301.[doi:10.3760/cma.j.issn.1673-4114.2016.04.013]
Zheng Xue,Sun Kai.Progress of dual-energy myocardial perfusion imaging by dual-source computed tomography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):301.[doi:10.3760/cma.j.issn.1673-4114.2016.04.013]
[10]张巍,杨珂.18f正电子放射性药物生产及使用中医务人员的受照剂量研究[J].国际放射医学核医学杂志,2015,39(5):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
zhang wei,yang ke..the research of radiation dose of 18f-fdg to pet/ct related personnel[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
[11]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[12]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[13]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[14]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[15]曹登敏,林美福,陈文新,等.继发性骨淋巴瘤的18F-FDG PET/CT影像学表现[J].国际放射医学核医学杂志,2016,40(6):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
Cao Dengmin,Lin Meifu,Chen Wenxin,et al.Analysis on 18F-FDG PET/CT imaging characteristics in secondary bone lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
[16]李生栩,唐明灯,林端瑜,等.18F-FDG PET/CT在胸段食管鳞癌淋巴结转移中的诊断价值[J].国际放射医学核医学杂志,2016,40(6):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
Li Shengxu,Tang Mingdeng,Lin Duanyu,et al.Value of 18F-FDG PET/CT in detecting metastatic lymph nodes of thoracic esophageal squamous cell carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
[17]张莹莹,王振光,武凤玉,等.特发性肺间质纤维化HRCT病变区与非病变区18F-FDG PET/CT表现分析[J].国际放射医学核医学杂志,2016,40(6):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
Zhang Yingying,Wang Zhenguang,Wu Fengyu,et al.18F-FDG PET/CT imaging analysis of regions with abnormal and normal pulmonary parenchyma on high resolution CT in idiopathic pulmonary fibrosis patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
[18]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[19]郝新忠,武志芳,武萍,等.SAPHO综合征18F-FDG PET/CT显像和临床分析[J].国际放射医学核医学杂志,2015,39(6):447.[doi:10.3760/cma.j.issn.1673-4114.2015.06.003]
Hao Xinzhong,Wu Zhifang,Wu Ping,et al.18F-FDG PET/CT imaging and clinical features of SAPHO syndrome[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):447.[doi:10.3760/cma.j.issn.1673-4114.2015.06.003]
[20]周文兰,吴湖炳,韩彦江,等.18F-FDG PET/CT对骨骼孤立性高代谢病灶的初步诊断价值[J].国际放射医学核医学杂志,2015,39(1):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]
Zhou Wenlan,Wu Hubing,Han Yanjiang,et al.Preliminary study of 18F-FDG PET/CT in the diagnosis of solitary hypermetabolic lesion of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]